X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Andrew Powaleny

Andrew Powaleny is Senior Director of Public Affairs at PhRMA and leads the organization's scientific communications. Before joining PhRMA in 2015, he worked in public affairs for a small firm in Washington, DC and served as Deputy Press Secretary for the House Committee on Energy and Commerce. Andrew came to Washington, D.C. via Connecticut with a degree from Eastern Connecticut State University where he majored in public policy and government. Andrew is active as a runner and volunteer with the DC Front Runners; most recently serving on its Board of Directors for three years as co-race director. He is also a member of the NLGJA: The Association of LGBTQ Journalists and mentors students through his alumni association with The Fund for American Studies. Andrew is passionate about scientific innovation, especially for mental illness, and his heroes are the men and women of America’s biopharmaceutical research companies.

Recent Posts

New data show continued decline in death rates for cancer patients related to treatment advances

By Andrew Powaleny  |    January 20, 2022
According to a new report from American Cancer Society (ACS), death rates for cancer patients in the United States continue to decrease. Each year, ACS details a range of incidence, mortality and...   Read More

Post-approval research save lives. Why is Congress trying disincentivize it?

By Andrew Powaleny  |    December 17, 2021
While some in Congress continue to claim the latest drug pricing plan in Washington is “negotiation,” that is far from the truth. The reality is that the current plan gives the government a new...   Read More

New Report: Nearly 800 new medicines in development to treat rare diseases

By Andrew Powaleny  |    December 16, 2021
Today, PhRMA released a new report detailing orphan drug development in the U.S. and the potential to meet the significant unmet medical need for patients. Rare diseases and conditions...   Read More

3 things to know about the importance of post-approval research and development

By Andrew Powaleny  |    December 6, 2021
Despite tremendous progress and knowledge gained from post-approval R&D, some in Congress still fail to recognize innovation doesn’t stop at U.S. Food and Drug Administration (FDA) approval. After...   Read More

World AIDS Day: Remembering those we’ve lost and exploring the continued fight against HIV/AIDS

By Andrew Powaleny  |    December 1, 2021
Today, as we mark World AIDS Day and commemorate those who lost their lives to AIDS-related illnesses, we want to recognize the impressive advancements in HIV/AIDS scientific research and drug...   Read More

ICYMI: PhRMA CEO speaks at STAT Summit about government price setting

By Andrew Powaleny  |    November 19, 2021
As part of the annual STAT Summit, PhRMA President and CEO Stephen J. Ubl recently spoke with STAT’s Matthew Herper to discuss the many unintended consequences expected from the latest drug...   Read More

New report shows more than 260 medicines in development to fight neurodegenerative diseases

By Andrew Powaleny  |    October 12, 2021
With neurodegenerative diseases affecting millions of individuals in the United States, now is an important time to spotlight the increasing impact these diseases have on our country’s aging...   Read More

Meeting Tomorrow: Looking ahead to PDUFA VII

By Andrew Powaleny  |    September 27, 2021
Tomorrow, PhRMA will participate at the U.S. Food and Drug Administration’s (FDA) public meeting on the reauthorization of the Prescription Drug User Fee Act (PDUFA VII).   Read More

The impact of monoclonal antibodies and COVID-19 recovery

By Andrew Powaleny  |    September 2, 2021
As the United States and world continue to fight the COVID-19 pandemic, America’s biopharmaceutical research companies continue to do our part in fighting this deadly virus. Decades of scientific...   Read More

Recognizing Hepatitis R&D on World Hepatitis Day

By Andrew Powaleny  |    July 28, 2021
Hepatitis is an inflammation of the liver, most commonly caused by a viral infection. There are five main hepatitis viruses, with types A, B, C most common. In 2018, the Centers for Disease...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates